Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.
Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.